141 related articles for article (PubMed ID: 37648808)
1. Treatment patterns in stage III non‑small‑cell lung cancer patients: a population‑based study using German cancer registry data.
Bedir A; Mehrotra S; Gnüchtel J; Vordermark D; Medenwald D
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15489-15497. PubMed ID: 37648808
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
4. Mortality after radiotherapy or surgery in the treatment of early-stage non-small-cell lung cancer: a population-based data analysis in the clinical cancer registry of Brandenburg-Berlin.
Müller JA; Vordermark D; Medenwald D
Strahlenther Onkol; 2023 Jul; 199(7):658-667. PubMed ID: 36912978
[TBL] [Abstract][Full Text] [Related]
5. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
[TBL] [Abstract][Full Text] [Related]
6. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
Sher DJ; Koshy M; Liptay MJ; Fidler MJ
Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group.
Ostheimer C; Mäurer M; Ebert N; Schmitt D; Krug D; Baumann R; Henkenberens C; Giordano FA; Sautter L; López G; Fleischmann DF; Niyazi M; Käsmann L; Kaul D; Thieme AH; Billiet C; Dobiasch S; Arnold CR; Oertel M; Haussmann J; Gauer T; Goy Y; Suess C; Ziegler S; Panje CM; Baues C; Trommer M; Skripcak T; Medenwald D
Strahlenther Onkol; 2021 May; 197(5):385-395. PubMed ID: 33410959
[TBL] [Abstract][Full Text] [Related]
8. Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center.
Thibodeau S; Meem M; Hopman W; Sandhu S; Zalay O; Fung AS; Kartolo A; Digby GC; Al-Ghamdi S; Robinson A; Ashworth A; Owen T; Mahmud A; Tam K; Olding T; de Moraes FY
Cancer Treat Res Commun; 2023; 36():100747. PubMed ID: 37531737
[TBL] [Abstract][Full Text] [Related]
9. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
[TBL] [Abstract][Full Text] [Related]
10. Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer.
Williams CD; Gajra A; Ganti AK; Kelley MJ
Cancer; 2014 Jul; 120(13):1939-47. PubMed ID: 24668613
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer.
Pichert MD; Canavan ME; Maduka RC; Li AX; Ermer T; Zhan PL; Kaminski M; Udelsman BV; Blasberg JD; Park HS; Goldberg SB; Boffa DJ
JAMA Netw Open; 2022 Aug; 5(8):e2224478. PubMed ID: 35925606
[TBL] [Abstract][Full Text] [Related]
12. Impact of time-to-treatment on survival for advanced non-small cell lung cancer patients in the Netherlands: a nationwide observational cohort study.
Klarenbeek SE; Aarts MJ; van den Heuvel MM; Prokop M; Tummers M; Schuurbiers OCJ
Thorax; 2023 May; 78(5):467-475. PubMed ID: 35450944
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.
Spence MM; Hui RL; Chang JT; Schottinger JE; Millares M; Rashid N
J Manag Care Spec Pharm; 2017 Feb; 23(2):195-205. PubMed ID: 28125366
[TBL] [Abstract][Full Text] [Related]
14. Changes in treatment patterns and survival in elderly patients with stage I non-small-cell lung cancer with the introduction of stereotactic body radiotherapy and video-assisted thoracic surgery.
Detillon DDEMA; Driessen EJM; Aarts MJ; Janssen-Heijnen MLG; van Eijck CHJ; Veen EJ
Eur J Cancer; 2018 Sep; 101():30-37. PubMed ID: 30014972
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
16. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
Langer C; Ravelo A; Hazard SJ; Guerin A; Ionescu-Ittu R; Latremouille-Viau D; Wu EQ; Ramalingam S
Lung Cancer; 2014 Dec; 86(3):350-7. PubMed ID: 25439437
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
Pan IW; Mallick R; Dhanda R; Nadler E
Lung Cancer; 2013 Dec; 82(3):469-76. PubMed ID: 24396885
[TBL] [Abstract][Full Text] [Related]
18. Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.
Bironzo P; Cani M; Jacobs F; Napoli VM; Listì A; Passiglia F; Righi L; Di Maio M; Novello S; Scagliotti GV
Cancer; 2023 Jun; 129(11):1662-1671. PubMed ID: 36905392
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis.
Hansen RN; Zhang Y; Seal B; Ryan K; Yong C; Darilay A; Ramsey SD
BMC Cancer; 2020 Apr; 20(1):276. PubMed ID: 32248816
[TBL] [Abstract][Full Text] [Related]
20. Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis.
Boyer MJ; Williams CD; Harpole DH; Onaitis MW; Kelley MJ; Salama JK
J Thorac Oncol; 2017 Dec; 12(12):1814-1823. PubMed ID: 28951090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
